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E-ISA247 (voclosporin) is a cyclosporin A analogue that is in
late-stage clinical development for the treatment of auto-
immune diseases and the prevention of organ graft rejection.
The X-ray crystal structures of E-ISA247 and its stereoisomer
Z-ISA247 bound to cyclophilin A have been determined and
their binding afﬁnities were measured to be 15 and 61 nM,
respectively, by ﬂuorescence spectroscopy. The higher afﬁnity
of E-ISA247 can be explained by superior van der Waals
contacts between its unique side chain and cyclophilin A.
Comparison with the known ternary structure including
calcineurin suggests that the higher immunosuppressive
efﬁcacy of E-ISA247 relative to cyclosporin A could be a
consequence of structural changes in calcineurin induced by
the modiﬁed E-ISA247 side chain.
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1. Introduction
Cyclosporin A (CsA) is a cyclic undecapeptide fungal meta-
bolite that is used for the prevention of acute rejection in
solid-organ transplantation (Graeb et al., 2004) and in the
treatment of psoriasis (Sobell & Hallas, 2003). CsA exerts its
immunosuppressive activity in a heterodimeric complex with
the peptidyl–prolyl cis–trans isomerase cyclophilin A (CypA;
Hamawy, 2003). Once formed, this complex binds to and
inhibits the calcium-dependent phosphatase calcineurin (Cn).
This prevents dephosphorylation of the transcriptional acti-
vator nuclear factor of activated T cells and its translocation
from the cytoplasm to the nucleus. Consequently, the pro-
duction of many immunosignalling cytokines is blocked and
the immune reaction is suppressed (Hamawy, 2003). However,
the long-term use of CsA is limited by side effects, notably
nephrotoxicity (Burdmann et al., 2003; Serkova et al., 2004;
Zachariae et al., 1997).
The ﬁrst X-ray structure of the CsA–CypA complex was
reported at 2.8 A ˚ resolution from tetragonal crystals (Pﬂugl
et al., 1993, 1994). Subsequently, CsA–CypA structures from
orthorhombic (Mikol et al., 1993) and monoclinic (Ke et al.,
1994) crystals that diffracted to 2.1 A ˚ resolution were
published. In addition, several crystal structures of CypA
complexed with different CsA derivatives and linear peptide
ligands have been reported (Taylor et al., 1997). Finally, X-ray
crystal structures of the ternary Cn–CypA–CsA complex were
solved at 2.8 and 3.1 A ˚ resolution (Huai et al., 2002; Jin &
Harrison, 2002). Analysis of the CsA–Cn interface suggested
that modiﬁcation of the butenyl group of the ﬁrst CsA residue
4-[(E)-2-butenyl]-4,N-dimethyl-l-threonine (Bmt1) might
optimize its ﬁt against the hydrophobic Cn surface and
therefore increase the binding afﬁnity.
In the continuous search for immunosuppressive com-
pounds with improved efﬁcacy and safety proﬁles, the racemicCsA derivative ISA247 has been developed (Aspeslet et al.,
2001). In the E isomer of ISA247 (E-ISA247; voclosporin)
the native MeBmt1 (Fig. 1a) is replaced by 4-[(2E,4EZ)-2,4-
pentadienyl]-4,N-dimethyl-l-threonine (E-MePmt1; Fig. 1b),
while in the Z isomer (Z-ISA247) this residue is replaced
by 4-[(2Z,4EZ)-2,4-pentadienyl]-4,N-dimethyl-l-threonine
(Z-MePmt1; Fig. 1c). E-ISA247 shows a greater immunosup-
pressive activity than CsA in vitro (Birsan et al., 2005) and in in
vivo animal models of autoimmunity (Maksymowych et al.,
2002) and transplantation (Aspeslet et al., 2001; Gregory et al.,
2004). Two Phase III trials investigating
the use of E-ISA247 for the treatment
of moderate to severe psoriasis, a Phase
IIb trial investigating the use of
E-ISA247 for the prevention of organ
graft rejection following kidney trans-
plantation and two Phase II/III trials
investigating the use of E-ISA247 for
the treatment of non-infectious uveitis
have been completed (Bissonnette et al.,
2006; Dumont, 2004).
Here, we report the X-ray crystal
structures of the CsA analogues
E-ISA247 (voclosporin) and Z-ISA247
bound to CypA. The equilibrium
dissociation constants of both CypA–
ISA247 complexes are determined and
are rationalized by the observed struc-
tural data. The impact of the stereo-
isomer conﬁguration of E-ISA247 on
the binding interaction with Cn and the
resulting immunosuppressive activity
are discussed.
2. Materials and methods
2.1. Protein production
The human CypA gene was inserted
into a pET21a plasmid and over-
expressed in Escherichia coli BL21
(DE3) cells. A 20 l culture was grown
at 303 K in LB medium and over-
expression was induced at an optical
density at 600 nm of 0.6 by adding IPTG
to a ﬁnal concentration of 0.5 mM. Cells
were harvested after 6 h. 150 g biomass
was resuspended in 750 ml of a buffer
consisting of 50 mM MES pH 6.5, 10%
saccharose, 5% glycerol, 10 mM MgCl2,
5m M TCEP, 0.02% NaN3,3 0 m g l
 1
DNase I and four tablets of Complete
protease-inhibitor cocktail (F. Hoff-
mann–La Roche) per litre. The cells
were disrupted, the lysate was micro-
ﬁltrated (0.2 mm) and concentrated by
ultraﬁltration (5 kDa) to about 200 ml
and the buffer was exchanged by dia-
ﬁltration to 20 mM sodium phosphate
pH 6.25, 2 mM TCEP, 5% glycerol,
0.02% NaN3 with four tablets of
Complete protease-inhibitor cocktail
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Figure 1
Residues at position 1 of CsA and the ISA247 stereoisomers. Structural formulae are displayed for
(a) the cyclosporin residue MeBmt1, (b) the E-ISA247 residue E-MePmt1 and (c) the Z-ISA247
residue Z-MePmt 1. 2Fo   Fc electron-density maps around (d) E-MePmt1 and (e) Z-MePmt1
contoured at one standard deviation above the mean density are displayed in green. Surface and
ball-and-stick representations of the crystal structures of CypA in grey complexed with (f) CsA
(PDB entry 2rma; Ke et al., 1994), (g) E-ISA247 and (h) Z-ISA247 in yellow are shown. The
distances between the Ala103 backbone carbonyl of CypA and residue 1 of the cyclic peptides are
marked by black arrows.(F. Hoffmann–La Roche) per litre. The protein solution was
loaded onto a Macro-Prep Ceramic Hydroxyapatite Type I
20 mm column (Bio-Rad) and eluted with a gradient from 20 to
500 mM sodium phosphate. The pooled CypA fractions were
dialysed against 20 mM MES pH 6.3, 1.5 mM TCEP, 0.02%
NaN3, loaded onto a Source 15S column (Amersham Bio-
sciences) and eluted with an NaCl gradient. Finally, CypA
was puriﬁed on a Superdex 75 Prep-Grade (Amersham Bio-
sciences) size-exclusion column equilibrated with 10 mM
sodium/potassium phosphate pH 6.0, 100 mM NaCl, 2 mM
TCEP, 0.02% NaN3.
2.2. Crystallization, X-ray data collection and model
refinement
For CypA–ISA247 complex formation, CypA was concen-
trated to 50 mg ml
 1 and mixed with 2 mME -ISA247 or
Z-ISA247. The solution was incubated for 30 min at room
temperature followed by 24 h on ice. The protein–peptide
complexes were crystallized in hanging drops by vapour
diffusion at 295 K using the same precipitant solution
consisting of 20%(w/v) PEG 3350, 100 mM MES pH 6.5 and
200 mM ammonium sulfate. For X-ray data collection at
100 K, the crystals were transferred to precipitant solution
containing an additional 20% glycerol and ﬂash-frozen with
liquid nitrogen. X-ray diffraction images of a CypA–E-ISA247
complex crystal were collected on a MAR345 image-plate
detector (MAR Research) using Cu K  radiation from a
Nonius FR591 rotating-anode X-ray generator. Images for
CypA–Z-ISA247 crystals were collected on a 165 mm MAR
CCD detector (MAR Research) using synchrotron radiation
on the Swiss Light Source X06SA beamline. CypA–E-ISA247
complex data were processed with the HKL program suite
(Otwinowski & Minor, 1997) to 2.2 A ˚ resolution in space
group P21 and CypA–Z-ISA247 data were processed to 2.3 A ˚
resolution in space group P212121 (see Table 1 for statistics).
Molecular-replacement solutions were obtained with the
program MOLREP (Vagin & Teplyakov, 2010) using the
CypA–CsA crystal structure (PDB entry 2rma; Ke et al., 1994)
as a search model. Ten CypA–inhibitor complexes were
identiﬁed in both space groups. Initial |Fo|   |Fc| maps calcu-
lated after rigid-body reﬁnement against the CypA–E-ISA247
and CypA–Z-ISA247 data clearly showed the additional C
atom of MePmt1 and the difference between its E and Z
isomers. Both structures were reﬁned by manual model ﬁtting
using the graphics program MOLOC (Gerber, 1992), model
reﬁnement using REFMAC5 (Murshudov et al., 1997) and the
placement of water molecules with ARP/wARP (Perrakis et
al., 1997). B factors were not restrained. 5% of the diffraction
data were excluded from the reﬁnement process for cross-
validation. In the ﬁnal models, the ten CypA–inhibitor
complexes in the respective asymmetric units are essentially
identical. The reﬁnement statistics are summarized in Table 1.
In the CypA–E-ISA247 structure Gly14 of chain M is poorly
deﬁned in the electron-density maps and is the only Rama-
chandran plot outlier. The coordinates and structure factors
of the CypA–E-ISA247 and CypA–Z-ISA247 structures have
been deposited in the Protein Data Bank with PDB codes 3odi
and 3odl, respectively.
2.3. Fluorescence spectroscopy
Fluorescence measurements were performed on an SLM-
Aminco 8100 double-grating spectroﬂuorometer using pre-
research papers
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Table 1
Data-collection and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
E-ISA247 Z-ISA247
PDB code 3odi 3odl
Space group P21 P212121
Unit-cell parameters (A ˚ ,  ) a = 69.2, b = 161.3,
c = 93.7,
  =   = 90.0,
  = 100.1
a = 132.4, b = 141.1,
c = 149.1,
  =   =   = 90.0
Copies per ASU† 10 10
X-ray source Cu K  SLS X06SA
Wavelength (A ˚ ) 1.5418 0.9799
Resolution range (A ˚ ) 25.0–2.2 (2.28–2.20) 40.0–2.3 (2.38–2.30)
No. of unique reﬂections 93907 (9188) 123151 (12158)
Completeness (%) 91.8 (88.0) 100.0 (100.0)
Multiplicity 3.3 (3.1) 9.5 (9.4)
Mean I/ (I) 13.3 (2.6) 22.1 (6.7)
Rmerge‡ 0.082 (0.399) 0.113 (0.424)
B factor from Wilson plot (A ˚ 2) 31.0 30.5
Rcryst 0.164 0.169
Rfree (%) 0.220 0.207
Root-mean-square deviations
Bond lengths (A ˚ ) 0.008 0.007
Bond angles ( ) 1.09 1.05
No. of protein residues/atoms 1644/12611 1650/12660
No. of ligand residues/atoms 110/860 110/860
No. of water molecules 1510 1726
Average B factor (A ˚ 2)
All atoms 36.4 24.4
Water molecules 44.6 34.4
Ramachandran plot statistics, residues in (%)
Favoured regions 96.2 96.4
Allowed regions 3.8 3.6
Outlier regions 0.1 0.0
† Number of CypA–ISA247 complexes per asymmetric unit in the crystal. ‡ Rmerge = P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.
Figure 2
Fluorescence titration curve of the E-ISA247 isomer. The measured
ﬂuorescence intensities after correction for protein dilution (dots) are
ﬁtted with a sigmoidal curve (line).viously described methods (Huber et al., 2004). The intrinsic
ﬂuorescence of CypA was excited through its single trypto-
phan at 280 nm and was detected at 340 nm. The equilibrium
dissociation constant Kd was determined by ﬂuorescence
titration at 200 nM protein concentration in 10 mM HEPES
pH 7.4, 150 mM NaCl. Aliquots of E-ISA247, Z-ISA247 and
CsA in DMSO were added to the protein solution (2 ml) and
the resulting ﬂuorescence intensities were measured. The ﬁnal
and constant DMSO concentration was 1.7%. The ISA247
isomers do not absorb at 280 nm and thus do not ﬂuoresce.
The measured ﬂuorescence intensities were corrected for
protein dilution (Birdsall et al., 1983). A plot of the corrected
ﬂuorescence intensity versus ligand concentration was ﬁtted
with a sigmoidal curve (Fig. 2), from which the Kd was com-
puted according to the law of mass action for a one-to-one
protein–ligand complex (Eftink, 1997). The reported Kd
values are averages from three titrations.
3. Results and discussion
3.1. ISA247 isomers do not induce major structural changes
in the drug–CypA complex
The structures of CypA complexed with E-ISA247 and
Z-ISA247 were determined at 2.2 and 2.3 A ˚ resolution,
respectively, with excellent quality of the electron density. In
both complexes, the structure of CypA, the backbone con-
formation of the ISA247 isomers and the nonsubstituted
ISA247 side chains 2–11 are essentially the same as in the
structure of the CypA–CsA complex (Ke et al., 1994). Signif-
icant differences between the three CypA–ligand structures
are only observed in the side-chain conformation of residue 1
of the undecapeptides (Figs. 1f–1h). The calculated electron-
density maps clearly show the elongated shape of the MePmt1
E isomer (Fig.1d) and the bent shape of the Z isomer (Fig. 1e).
We conclude that the chemical modiﬁcations of the ISA247
isomers at residue 1 (Figs. 1a–1c) do not induce major re-
arrangements of the CypA side chains in the drug–CypA
complex and that functional differences between the two
ISA247 isomers result from the structural difference at the
modiﬁed MePmt1 residue only.
3.2. ISA247 stereoisomers differ in their interaction with
CypA
We have determined the binding afﬁnities of E-ISA247,
Z-ISA247 and CsA to its pharmacological binding partner
CypA using ﬂuorescence spectroscopy. The afﬁnity of
E-ISA247, with a Kd value of 15   4n M, is essentially the
same as the Kd of 13   4n M found for CsA. Z-ISA247,
however, binds to CypA with an approximately fourfold
higher dissociation constant (Kd =6 1  9n M). This further
strengthens the decision made early in the development of
voclosporin to focus on the E isomer of ISA247 rather than to
progress with the easier-to-produce racemate.
The only signiﬁcant difference in the crystal structures of
CypA complexed with Z-ISA247, E-ISA247 and CsA is
observed in the side-chain conformation of the undecapeptide
residue 1 (Figs. 1f–1h). In the CypA–CsA complex MeBmt1
is positioned at the calcineurin-binding composite surface,
between the CsA residues N-methylated leucine (MeLeu) 4,
MeLeu6 and MeLeu10 on one side and the CypA residues
Asn102, Ala103, Gly104 and His126 on the other side (Fig. 1f).
The MeBmt1 side chain is in van der Waals contact with the
Ala103 backbone atoms. In the crystal structures of E-ISA247
(Fig. 1g) and Z-ISA247 (Fig. 1h) bound to CypA, the inter-
action patterns between the modiﬁed MePmt1 side chains and
the Ala103 backbone differ from the pattern observed in the
CypA–CsA structure (Fig. 1f). While E-MePmt1 and MeBmt1
demonstrate high van der Waals complementarity with CypA,
Z-MePmt leaves a gap between the protein and Z-ISA247.
This is reﬂected in the distances of the CypA Ala103 carbonyl
groups to the MeBmt1 (4.0 A ˚ ), E-MePmt1 (3.5 A ˚ ) and
Z-MePmt (5.0 A ˚ ) CZ atoms in the respective structures. We
suggest that lack of surface complementarity between CypA
and Z-MePmt is the reason for the reduced afﬁnity of the CsA
analogue Z-ISA247.
3.3. Impact of MeBmt1 modifications on Cn inhibition
CsA binds to CypA and this heterodimeric complex binds
to and inhibits calcineurin, inducing immunosuppression.
The X-ray crystal structures of the ternary Cn–CypA–CsA
complex show that the binary CypA–CsA complex binds to a
composite surface made up of residues from the Cn catalytic
and regulatory subunits (Huai et al., 2002; Jin & Harrison,
2002). In many cases the biological activity of CsA derivatives
correlate with their afﬁnity for CypA, but notable exceptions
have been reported (Kallen et al., 1998). In general, modiﬁ-
cations at the CypA-binding residues 1, 2, 9, 10 or 11 that
research papers
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Figure 3
Superposition of the ternary Cn–CypA–CsA complex with the binary
CypA–ISA247 complexes. Cn, CypA and the CsA residue MeBmt1 of the
ternary complex (PDB entry 1m63; Huai et al., 2002) are displayed in
yellow, grey and pink, respectively. The MePmt1 residues of E-ISA247
and Z-ISA247 are shown in green and cyan, respectively. A close contact
between E-ISA247 and Cn (carbon-to-nitrogen distance of 2.4 A ˚ )i s
marked by a black arrow.diminish binding to CypA also result in diminished immuno-
suppressive activity, while modiﬁcations of the effector-loop
residues 4, 5 or 6 can strongly affect the immunosuppressive
activity without signiﬁcantly affecting CypA binding (Kallen
et al., 1998; Taylor et al., 1997). E-ISA247 exempliﬁes an
exception to this rule: it shows afﬁnity for CypA comparable
with that of CsA but superior immunosuppressive activity
(Birsan et al., 2005). To analyze the structural basis for this
observation, we superimposed the CypA C
  atoms of the
binary CypA–ISA247 complexes with the CypA C
  atoms of
the ternary Cn–CypA–CsA complex and analysed the
ISA247–Cn interfaces of the resulting Cn–CypA–ISA247
structure models (Fig. 3). Interestingly, the interaction
patterns between Cn and the ISA247 isomers differ markedly
from that observed with CsA. In the E-ISA247 ternary-
complex superposition model the distance between the side
chains of E-MePmt1 and the Cn residue Asn122 is only 2.4 A ˚ .
This demonstrates that at least one of these two amino acids
has to adopt a signiﬁcantly different conformation in order to
avoid repulsion. Very limited conformational ﬂexibility has
been observed for the MeBmt1 side chain of CsA in the
published CypA complex crystal structures, indicating that the
Cn residue Asn122 is more likely to be affected. The modiﬁ-
cation of the ﬁrst residue of E-ISA247 is unlikely to signiﬁ-
cantly change its conformational ﬂexibility, in contrast to the
modiﬁcation of the fourth residue of the CsA analogue Debio
025, which not only limits the number of available side-chain
conformations but also prevents binding of the Debio 025–
CypA complex to Cn (Landrieu et al., 2010). Asn122 is part of
the so-called ‘latch region’ of the Cn regulatory subunit (Huai
et al., 2002; Jin & Harrison, 2002). This loop region is involved
in activation of the Cn catalytic subunit and amino-acid sub-
stitutions within this loop induce varying degrees of CsA
resistance (Milan et al., 1994). It has been suggested that
modulation of Cn activity by CypA–CsA might be not only a
consequence of spatial blockade of protein substrates but also
of a direct involvement of CypA–CsA in the regulation of Cn
activity (Huai et al., 2002). This would provide one possible
explanation for the differential immunosuppressive activities
of the equipotent CypA binders E-ISA247 and CsA. Another
possible explanation would be that the CypA–E-ISA247
complex binds to Cn with higher afﬁnity as a result of the
predicted structural changes at the Cn–E-ISA247 interface
around residue E-MePmt1.
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